SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like California Cannabis Growers Now Have Access To Safe And Effective Biopesticides From Marrone Bio Innovations, Inc June 11, 2017 Array BioPharma And Bristol-Myers Squibb Announce Strategic Collaboration May 29, 2017 After $40M Financing, Exonics Therapeutics to Start Hiring for Cambridge Lab November 8, 2017
California Cannabis Growers Now Have Access To Safe And Effective Biopesticides From Marrone Bio Innovations, Inc June 11, 2017